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that (i.e., retreatment); 3) Annualized resource use stratiﬁed by
retreatment status. RESULTS: Of the 45 patients who met study
inclusion criteria, mean age was 61.8 and 62.2% were male.
46.7% of patients (n = 21) had medication use >1 month after
the recommended treatment regimen. 73.3% (n = 33) had a gap
in treatment, and of these, 24.2% (n = 8) were retreated after
the gap. Annualized resource utilization (mean (SD)) for not
retreated vs. retreated patients respectively was: Physician visits:
2.0 (2.0) vs. 4.2 (3.9), p = 0.16; Specialist visits: 1.0 (2.1) vs. 2.7
(2.9), p = 0.16; SAP tests: 0.3 (0.8) vs. 0.8 (2.8), p = 0.32; and
Bisphosphonate prescriptions: 1.7 (2.3) vs. 4.2 (3.9), p = 0.12.
CONCLUSIONS: This analysis of real-world treatment patterns
and resource use in risedronate-treated patients suggests a large
extent of risedronate use beyond approved label recommenda-
tions and high retreatment rates, as well as higher resource use
in those retreated. Larger studies are warranted to further under-
stand treatment patterns and associated resource utilization in
Paget’s disease patients.
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OBJECTIVES: Cost-effectiveness analyses are routinely based on
data from group averages, restricting its generalizibility to those
with below- or above-average risk. A pharmaco-economic model
was developed that used individualised risks, taking as example
bisphosphonates and prevention of fractures. METHODS: Data
were obtained from a research database of general practitioners,
comprising a sample of the UK general population of women 
>50 years (N = 330,000). Individual mortality and hip, verte-
bral, and other osteoporotic fracture risks were estimated by age,
sex, body mass index, smoking and other clinical risk factors.
Estimates on costs, EQ5D utilities and treatment efﬁcacy were
obtained from a UK national report (NICE) and outcomes were
simulated over a ten-year period. RESULTS: There was a large
variability in the cost-effectiveness with clinical risk factors. At
age 60–69, the cost per QALY gained was ≤136k in women with
low fracture risk but ≤36k with high fracture risk (data for
women without fracture history). Patients with low body mass
index (<20) had considerable better cost-effectiveness than
patients with high BMI (≥26) (≤23k versus ≤71k at age 60–79
in women without fracture history). The same was found for dif-
ferent diseases such as rheumatoid arthritis or inﬂammatory
bowel disease. Using a cost-acceptability ratio of ≤30k per
QALY gained, bisphosphonates became cost-effective for
patients with a ﬁve-year risk of 9.3% (95% CI 8.0–10.5%) for
osteoporotic fractures and of 2.1% (95% CI 1.5–2.7%) for hip
fractures. Including bone mineral density in the risk assessment,
the cost per QALY gained was ≤35k in women at age 60 with
a fracture history and a T-score of -2.5 (at age 80, this was 
≤3k). CONCLUSIONS: A pharmaco-economic model based on
individual long-term risks (as derived from a health care data-
base) can improve the targeting in a cost-effective manner of
therapy to patients.
OSTEOPOROSIS—Patient Reported Outcomes
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OBJECTIVES: To assess patient adherence with bisphospho-
nates at 6 months of therapy utilizing an integrated administra-
tive, medical and pharmacy claims database. METHODS: A
retrospective cohort study was conducted among 128,362
women, 45 years of age and older, with a new (index) prescrip-
tion for risedronate (35mg/week) or alendronate (35mg/week or
70mg/week) between May 1, 2002, and December 31, 2003. All
eligible patients were required to be continuously enrolled for
the six months preceding and the 12 months following the index
date and to have ﬁlled at least 2 continuous bisphosphonate pre-
scriptions, as deﬁned below. The six-month history was used to
assess baseline clinical characteristics, including fracture history,
gastrointestinal conditions, hospitalizations, and glucocorticoid
use. Adherence with therapy was then assessed for the ﬁrst 6
months of bisphosphonate treatment. Patient adherence was
deﬁned as continuous reﬁlling of the weekly bisphosphonate
treatment with no gaps exceeding 90 days during the follow-up
period. RESULTS: The average bisphosphonate user in this study
was aged 64 years; 78% initiated with alendronate and 22%
with risedronate. Almost 4% had a history of fragility fractures
(vertebral and/or non-vertebral) and 18% used oral glucocorti-
coids during the study period. At 6 months, 71% of bisphos-
phonate patients were adherent with therapy. An additional 22%
discontinued, and subsequently resumed treatment after a mean
treatment gap of 164 days. The following patient characteristics
were correlated with a higher likelihood of therapy discontinu-
ation: younger age, GI event after the index date, oral glucocor-
ticoid use, and history of GI events, hospitalization, or fracture.
CONCLUSIONS: This study demonstrates that seven in ten new
bisphosphonate users remained on therapy at six months after
treatment initiation. An additional two in ten patients resumed
therapy after a mean treatment gap of ﬁve months. Overall, the
majority of patients who initiated bisphosphonates were adher-
ent after the ﬁrst six months of treatment.
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OBJECTIVES: To determine the rates of compliance; discontin-
uation; and switching of treatment with bisphosphonates, calci-
tonin, estrogens, parathyroid hormones, and raloxifene in
Louisiana Medicaid post-menopausal women with diagnosis of
osteoporosis and/or fracture. METHODS: Medical and phar-
macy administrative claims data obtained from the Louisiana
Department of Health and Hospitals were used for the study.
The data contain paid claims for all Louisiana Medicaid recipi-
ents. Women age 50 and older diagnosed with osteoporosis
and/or a fracture between July 1, 2002 and June 30, 2003 and
continuously eligible 12 months prior through 24 months after
their initial diagnosis were included in the study. Women with
Medicare eligibility and those who received a prescription for
osteoporosis and/or fracture 12 months prior were excluded.
There were 1772 women who met the inclusion criteria. Claims
data on these women were studied for two years from the date
of their initial diagnosis. Women were considered compliant if
the difference between their ﬁll dates did not exceed 45 days.
Women were considered discontinuers if they ﬁlled prescriptions
only once in the two-year study period. Recipients were consid-
ered switchers if they switched from one drug to another, single
to combination therapy, or combination to single therapy.
RESULTS: Of the 1772 in the study group, 28% (500) received
treatment, and of those, 57% were on a single drug, 22% on
multiple drugs, and 21% discontinued treatment. The compli-
